Wells Fargo raised the firm’s price target on NeuroPace to $9 from $6 and keeps an Equal Weight rating on the shares after a different analyst took over coverage of the name. The firm’s price target reflects the company’s revenue growth profile, ongoing management execution and a large market opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NPCE:
- NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
- NeuroPace to participate in a conference call with Lake Street
- NeuroPace management to meet virtually with Lake Street
- NeuroPace to Participate in Upcoming Investor Conferences
- NeuroPace upgraded to Equal Weight from Underweight at Morgan Stanley